scholarly journals "It's Beyond Water": Stories of Women’s Experience of Using Water for Labour and Birth

2021 ◽  
Author(s):  
◽  
Robyn Maude

<p><b>This study looks at stories of women’s experience of using water for labour and birth and has explored them to reveal the meaning women make of the experience.</b></p> <p>Randomised controlled trials report that there are no statistically significant differences in the outcomes for women who use water when compared to those who do not. It has also established that there are no adverse effects on the mother and baby. However, most of the research to date largely ignores what women have to say about the use of water for labour and birth. This study employed an interpretive design using audio-taped conversations with women as the method of data collection, and a thematic analysis of the stories, to identify the meaning women make of their experiences. The research is informed by a feminist perspective, which honours the women’s voices and knowledge.</p> <p>The women's stories reveal that the all-encompassing warmth associated with being enveloped in warm water cradles, supports, relaxes, comforts, soothes, shelters and protects the woman, creates a barrier and offers her a sense of privacy. Water can be used in any form, even the act of thinking about, preparing for and anticipating the water opens possibilities for women. Women use water to reduce their fear of pain and of childbirth itself. Women use water to cope with pain, not necessarily to remove or diminish pain and to maintain control over the process of birth. It is not necessary to actually give birth in the water to achieve these benefits.</p> <p>Recommendations for midwifery practice include the need for midwives to reflect on their role as guardians of normal birth by examining their personal philosophy of birth, critically examining their outcomes and honouring women's knowledge.</p>

2021 ◽  
Author(s):  
◽  
Robyn Maude

<p><b>This study looks at stories of women’s experience of using water for labour and birth and has explored them to reveal the meaning women make of the experience.</b></p> <p>Randomised controlled trials report that there are no statistically significant differences in the outcomes for women who use water when compared to those who do not. It has also established that there are no adverse effects on the mother and baby. However, most of the research to date largely ignores what women have to say about the use of water for labour and birth. This study employed an interpretive design using audio-taped conversations with women as the method of data collection, and a thematic analysis of the stories, to identify the meaning women make of their experiences. The research is informed by a feminist perspective, which honours the women’s voices and knowledge.</p> <p>The women's stories reveal that the all-encompassing warmth associated with being enveloped in warm water cradles, supports, relaxes, comforts, soothes, shelters and protects the woman, creates a barrier and offers her a sense of privacy. Water can be used in any form, even the act of thinking about, preparing for and anticipating the water opens possibilities for women. Women use water to reduce their fear of pain and of childbirth itself. Women use water to cope with pain, not necessarily to remove or diminish pain and to maintain control over the process of birth. It is not necessary to actually give birth in the water to achieve these benefits.</p> <p>Recommendations for midwifery practice include the need for midwives to reflect on their role as guardians of normal birth by examining their personal philosophy of birth, critically examining their outcomes and honouring women's knowledge.</p>


2017 ◽  
Vol 2017 ◽  
pp. 1-12 ◽  
Author(s):  
Ya-Fei Liu ◽  
Ying Huang ◽  
Cai-Yu-Zhu Wen ◽  
Jun-Jun Zhang ◽  
Guo-Lan Xing ◽  
...  

The modified Simiao decoctions (MSD) have been wildly applied in the treatment of gouty arthritis in China. However, the evidence needs to be evaluated by a systematic review and meta-analysis. After filtering, twenty-four randomised, controlled trials (RCTs) comparing the effects of MSD and anti-inflammation medications and/or urate-lowering therapies in patients with gouty arthritis were included. In comparison with anti-inflammation medications, urate-lowering therapies, or coadministration of anti-inflammation medications and urate-lowering therapies, MSD monotherapy significantly lowered serum uric acid (p<0.00001, mean difference = −90.62, and 95% CI [−128.38, −52.86];p<0.00001, mean difference = −91.43, and 95% CI [−122.38, −60.49];p=0.02, mean difference = −40.30, and 95% CI [−74.24, −6.36], resp.). Compared with anti-inflammation medications and/or urate-lowering therapies, MSD monotherapy significantly decreased ESR (p<0.00001; mean difference = −8.11; 95% CI [−12.53, −3.69]) and CRP (p=0.03; mean difference = −3.21; 95% CI [−6.07, −0.36]). Additionally, the adverse effects (AEs) of MSD were fewer (p<0.00001; OR = 0.08; 95% CI [0.05, 0.16]). MSD are effective in the treatment of gouty arthritis through anti-inflammation and lowering urate. However, the efficacy of MSD should be estimated with more RCTs.


BJPsych Open ◽  
2016 ◽  
Vol 2 (1) ◽  
pp. 59-66 ◽  
Author(s):  
Ying Jiao Zhao ◽  
Liang Lin ◽  
Monica Teng ◽  
Ai Leng Khoo ◽  
Lay Beng Soh ◽  
...  

BackgroundFor treatment of patients diagnosed with schizophrenia, comparative long-term effectiveness of antipsychotic drugs to reduce relapses when minimising adverse effects is of clinical interest, hence prompting this review.AimsTo evaluate the comparative long-term effectiveness of antipsychotic drugs.MethodWe systematically searched electronic databases for reports of randomised controlled trials (RCTs) of antipsychotic monotherapy aimed at reducing relapse risks in schizophrenia. We conducted network meta-analysis of 18 antipsychotics and placebo.ResultsStudies of 10 177 patients in 56 reports were included; treatment duration averaged 48 weeks (range 4–156). Olanzapine was significantly more effective than chlorpromazine (odds ratio (OR) 0.35, 95% CI 0.14–0.88) or haloperidol (OR=0.50, 95% CI 0.30–0.82); and fluphenazine decanoate was more effective than chlorpromazine (OR=0.31, 95% CI 0.11–0.88) in relapse reduction. Fluphenazine decanoate, haloperidol, haloperidol decanoate and trifluoperazine produced more extrapyramidal adverse effects than olanzapine or quetiapine; and olanzapine was associated with more weight gain than other agents.ConclusionsExcept for apparent superiority of olanzapine and fluphenazine decanoate over chlorpromazine, most agents showed intermediate efficacy for relapse prevention and differences among them were minor. Typical antipsychotics yielded adverse neurological effects, and olanzapine was associated with weight gain. The findings may contribute to evidence-based treatment selection for patients with chronic psychotic disorders.


2021 ◽  
Vol 19 ◽  
Author(s):  
Leonardo Gomes Pereira ◽  
Gabriela Trevisan ◽  
Patrícia Rodrigues ◽  
Fernanda Tibolla Viero ◽  
Julia Maria Frare ◽  
...  

: Multiple sclerosis (MS) is a chronic neurodegenerative, inflammatory and autoimmune disease characterised by the demyelination of the central nervous system. One of the main approaches to treating MS is the use of disease-modifying therapies (DMTs). Among the DMTs are interferons (IFNs), which are cytokines responsible for controlling the activity of the immune system, exerting immunomodulatory, antiviral, and antiproliferative activities. IFN-beta (IFN-β) is the first-choice drug used to treat relapsing-remitting MS. However, the administration of IFN-β causes numerous painful adverse effects, resulting in lower adherence to the treatment. Therefore, this study aimed to investigate the headache and flu-like pain symptoms observed after IFNβ injection in MS patients using a systematic review and meta-analysis of randomised controlled trials. The search of research databases identified 2370 articles. Nine articles were included (three involving IFNβ-1b and six involving IFNβ-1a). All studies included in the meta-analysis had a low risk of bias. Headache and flu-like pain symptoms frequency increased in MS patients treated with IFN-β. Thus, the adverse effects of headache and flu-like pain symptoms appear to be linked to IFN-β treatment in MS. The protocol of the study was registered in the Prospective International Registry of Systematic Reviews.


2002 ◽  
Vol 175 (2) ◽  
pp. 545-552 ◽  
Author(s):  
J Bryant ◽  
E Loveman ◽  
C Cave ◽  
D Chase ◽  
R Milne

We have evaluated the reporting of withdrawals due to adverse effects and specific adverse effects in randomised controlled trials of recombinant human GH in adults. A systematic review was carried out of randomised controlled trials of the clinical effectiveness of recombinant human GH in adults with GH deficiency in relation to impact on quality of life. Trials were identified from searching electronic databases, bibliographies of related articles and consulting experts. There was reporting of withdrawals due to adverse effects and specific adverse effects. Rates of oedema and arthralgia were reported in included trials. Seventeen randomised controlled trials, published between 1990 and 1999, met the inclusion criteria for the review. Nine trials reported data on the effectiveness of GH on quality of life in adults. Only five trials (29%) reported both withdrawals from the study because of adverse events and specific adverse events with numbers per study arm and per type. Six further trials (35%) reported either withdrawal details or specific adverse event details or partial data on specific adverse events. Six trials (35%), however, did not report information on either withdrawals or specific adverse events. Ten of the 17 studies (59%) reported the number of patients who withdrew from the study due to adverse events per study arm and type of adverse event per study arm. Seven of the 17 trials (41%) reported the number of specific adverse events per study arm and six (35%) reported the type per study arm. The reporting of adverse events in randomised controlled trials of GH is variable and not consistent across trials. It is not possible to assess the impact that adverse events may have had on unblinding patients, and therefore the extent to which the effects of GH may have been overestimated. Therefore those conducting endocrinology trials in the future need to pay attention to the reporting of withdrawals due to adverse events and specific adverse events.


BDJ Open ◽  
2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Erica Martin ◽  
Alan Nimmo ◽  
Andrew Lee ◽  
Ernest Jennings

Abstract Objectives To comprehensively review the existing studies of articaine in dentistry and conduct a systematic review and meta-analysis to answer the following Population, Intervention, Comparison and Outcome question: “Is articaine a safe and efficacious local anaesthetic for routine dental treatment compared to lidocaine?” Methods Database searches were conducted in Medline Ovid, Medline Pubmed, Scopus, Emcare, Proquest and the Cochrane Central register of Controlled Trials. Inclusion criteria were all existing English, human, randomised controlled trials of interventions involving 4% articaine and 2% lidocaine in routine dental treatment. Twelve studies were included for meta-analysis using Cochrane Review Manager 5 software. Anaesthetic success odds ratios were calculated using a random-effects model. Results Articaine had a higher likelihood of achieving anaesthetic success than lidocaine overall and in all subgroup analyses with varying degrees of significance. Overall (OR: 2.17, 95% CI: 1.50, 3.15, I2 = 62%) articaine had 2.17 times the likelihood of anaesthetic success of lidocaine (P < 0.0001). For mandibular blocks (OR: 1.50, 95% CI: 1.14, 1.98, I2 = 0%) articaine had 1.5 times the likelihood of anaesthetic success of lidocaine (P = 0.004). For all infiltrations, maxillary and mandibular (OR: 2.78, 95% CI: 1.61, 4.79, I2 = 66%) articaine had 2.78 times the likelihood of anaesthetic success of lidocaine (P = 0.0002). None of the studies reported any major local anaesthetic-related adverse effects as a result of the interventions. Conclusions Articaine is a safe and efficacious local anaesthetic for all routine dental procedures in patients of all ages, and more likely to achieve successful anaesthesia than lidocaine in routine dental treatment. Neither anaesthetic has a higher association with anaesthetic-related adverse effects.


Sign in / Sign up

Export Citation Format

Share Document